HPV Vaccines Market Report
Global HPV Vaccines Market report is segmented By Type (Bivalent, Polyvalent), By Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer, Genital Warts, Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others) and Region. This market research report provides in-depth information on trends, dynamics, revenue opportunities, competitive landscape, and recent developments in the global HPV vaccines market. The historic years considered for the study are 2016-2019, the base year is 2020, the estimated year is 2021, and the forecast period is 2022-2026.
Global HPV Vaccines Market report is segmented By Type (Bivalent, Polyvalent), By Indication (Cervical Cancer, Anal Cancer, Penile Cancer, Oropharyngeal Cancer, Genital Warts, Others), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others) and Region...
The Global HPV Vaccines Market is projected to grow from USD 4.82 billion in 2020 to USD 11.79 billion by 2026 at a CAGR of over 16.1% during the forecast period.
Figure: Global HPV Vaccines Market Size, 2020-2026 (USD Billion)
Wish to get a sample report? Click here.
Human papillomavirus (HPV) infection is one of the most common sexually transmitted infections which is caused by HPV-related cancers, such as genital and cervical cancers. HPV infection vaccines are primarily used to prevent genital warts, cervical cancer, anal cancer, and vaginal cancer. Three commercially available HPV prevention vaccines, such as Gardasil 9 and Gardasil by Merck and Cervarix developed by GSK Plc, are known to be highly effective in preventing HPV infection and genital precancerous lesions.
Key players operating in the global HPV vaccines market are-
The rising prevalence of cervical cancer among women is a prime factor augmenting the demand for HPV vaccines.
By type, the global HPV vaccines market has been bifurcated into bivalent, polyvalent.
By region, the North American market witnessed the highest market share in 2020 and is estimated to register at a considerable CAGR during the review period. This is mainly attributed to the strong presence of well-established healthcare facilities, along with the ease in the availability of necessary resources. Moreover, people are aware of the presence of vaccines and related therapeutic procedures, thus augmenting the for vaccination and treatment, further boosting the regional growth.
The outbreak of the COVID-19 virus had a devastating impact on the HPV vaccine industry. The healthcare industry is currently facing major challenges as it is unable to provide proper medical facilities to cater to the ever-growing coronavirus patient pool. With the stringent imposition of lockdown and social distance regulations, there were limited check-ups of women suffering from sexually transmitted diseases. During the pandemic period in 2020, around 342,000 women lost their lives due to cervical cancer. Thus, a poor healthcare system due to limited medical professionals and funding affected the market growth.
Want to know the full scope of the report? Register Here
Here is the list of the group of customers that the HPV Vaccine market hopes to have the greatest opportunity to convert-
Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].
The HVP vaccines market size is expected to reach USD 11.79 billion in the foreseeable future.
The HVP vaccines market is expected to witness an impressive growth of 16.1% CAGR in the coming years.
Lumetrics (The U.S), Marco (The U.S), Voptica (Spain), AMICO GROUP (UAE), NIDEK (Japan), Hanson Instruments (UK), Alcon (Switzerland), Carl Zeiss (Germany), Essilor (France), and Johnson & Johnson Visioncare Inc. (US) are among the key players in the HVP Vaccines Market.
North America Witnessed highest share in the HVP vaccines market in 2020.
The polyvalent segment accounted for the highest share in the HVP vaccines market in 2020.
Rising prevalence of cervical cancer among women, the growing need to reduce HPV infections are the factors driving the growth of HVP vaccines market.
HPV Vaccines companies, HPV Vaccines vendors, Cancer organizations, Sexually transmitted diseases treatment companies, Hospitals are the target audience in the HVP vaccines market.